Association for Molecular Pathology (AMP) 2022
We are headed to Phoenix for AMP 2022! Visit us at Booth #1521 for a first hand experience of the Spatial Biology Ecosystem (GeoMx Digital Spatial Profiler, CosMx Spatial Molecular Imager and the new AtoMx Spatial Informatics Platform), and latest advancements utilizing the nCounter Pro platform.
CORPORATE WORKSHOP DAY: Wednesday, Nov. 2
8:00 – 8:50AM Spatial Biology innovations pathway to the clinic (session 1 of 2)
Speaker: Dr. Grant Kolar, St. Louis University
Join us for the first of two informative sessions to learn about the latest innovations in Spatial Biology and the path to clinical utility. Session one will deliver an overview of spatial biology from whole transcriptomics and high-plex spatial proteomics to multiomic, single-cell and subcellular resolution spatial imaging. Joseph Beechem will highlight NanoString’s entire spatial ecosystem, the GeoMx Digital Spatial Profiler, CosMx Spatial Molecular Imager, and AtoMx Spatial Informatics Platform. In closing, Dr. Grant Kolar, St Louis University, will present his study of Diabetic Kidney disease using both GeoMx DSP and CosMx SMI spatial technologies.
9:00 – 9:50AM Spatial Biology innovations pathway to the clinic (session 2 of 2)
Speakers: Dr. Jodi Carter, University of Alberta & Dr. Tae Hyun Hwang, Florida Department of Health and Mayo Clinic
Immediately following Session 1, you will hear from Dr. Jodi Carter, University of Alberta, formerly of Mayo Clinic. Dr. Carter has been working with OHSU to develop a high-plex, spatial proteomic solution on GeoMx DSP while making novel single cell discoveries with CosMx SMI. Following, you will hear from Dr. Tae Hyun Hwang, Florida Department of Health and Mayo Clinic, who has been studying Gastric cancers and uses various analytical tools from his digital pathology toolbox. Finally, we will wrap up our sessions with a panel discussion with all our speakers and provide Q&A with the audience.
10:00 – 10:50AM Lymph2Cx/Lymph3Cx from bench to clinic- developing genomic tests that guide DLBCL diagnosis and treatment using the nCounter platform.
Speakers: Colleen Ramsower, M.S., Molecular Diagnostics AZ Lab (MDAZL), Mayo Clinic, Scottsdale, AZ, Ryan Robetorye, M.D., Ph.D., Molecular Diagnostics AZ Lab (MDAZL), Mayo Clinic, Phoenix, AZ, and Joseph Beechem, Ph.D. NanoString Inc.
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that includes distinct cell of origin subtypes which can have significantly different prognoses and survival rates. Primary mediastinal B cell lymphoma (PMBCL) can be difficult to distinguish from DLBCL on clinicopathologic features alone. Join us as colleagues from the Mayo clinic share how they used digital gene expression profiling on the nCounter® platform to develop and validate a cell of origin assay to molecularly subtype DLBCL as well as an assay to differentiate it from PMBCL. Hear their experiences establishing a CAP/CLIA-certified molecular laboratory to offer the tests to patients.
